Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesin and cisplatin in unresectable stage III non small-cell lung cancer

Renard A; Noel G; Mazeron JJ

首页> 外文期刊>Cancer radiotherapie: journal de la Soci閠?fran鏰ise de radiotherapie oncologique >Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesin and cisplatin in unresectable stage III non small-cell lung cancer

【24h】

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesin and cisplatin in unresectable stage III non small-cell lung cancer

机译：不可切除的III期非小细胞肺癌同时胸腔放疗与序贯胸腔放疗联合丝裂霉素，vindesin和顺铂的III期研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Cancer radiotherapie: journal de la Soci閠?fran鏰ise de radiotherapie oncologique》 |2000年第4期|共2页
作者
Renard A; Noel G; Mazeron JJ;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 fre
中图分类肿瘤学;
关键词
Antineoplastic Agents; Combined; Carcinoma; Non-Small-Cell Lung; Lung Neoplasms; 抗肿瘤药; 多剂联用; 癌; 非小细胞肺; 肺肿瘤;

机译：Antineoplastic Agents;Combined;Carcinoma;Non-Small-Cell Lung;Lung Neoplasms;抗肿瘤药;多剂联用;癌;非小细胞肺;肺肿瘤;

相似文献

外文文献
中文文献
专利

1. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesin and cisplatin in unresectable stage III non small-cell lung cancer [J] . Renard A, Noel G, Mazeron JJ Cancer radiotherapie: journal de la Soci閠?fran鏰ise de radiotherapie oncologique . 2000,第4期

机译：不可切除的III期非小细胞肺癌同时胸腔放疗与序贯胸腔放疗联合丝裂霉素，vindesin和顺铂的III期研究
2. 9104 Randomized phase III study of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (CTR) for patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): West Japan Thoracic Oncology Group (WJTOG) 0105 [J] . N.Katakami, M.Satouchi, N.Yamamoto, European Journal of Cancer Supplements . 2009,第2期

机译：9104丝裂霉素/长春地辛/顺铂（MVP）与每周伊立替康/卡铂（IC）或每周紫杉醇/卡铂（PC）联合胸腔放疗（CTR）的不可切除的III期非小细胞患者的3期随机研究肺癌（NSCLC）：西日本胸腔肿瘤小组（WJTOG）0105
3. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. [J] . Takada M, Fukuoka M, Kawahara M, Journal of Clinical Oncology . 2002,第14期

机译：同期放疗和序贯胸放疗联合顺铂和依托泊苷治疗有限期小细胞肺癌的III期研究：日本临床肿瘤小组研究9104的结果。
4. Early Assessment of the Added Value of FDG-PET/CT and MRI-DWI in Monitoring Treatment Response of Stage III Non-Small Cell Lung Cancer [C] . K.R. Siegersma, J.M. Hummel, H. Broekhuizen Mediterranean Conference on Medical and Biological Engineering and Computin . 2016

机译：早期评估FDG-PET / CT和MRI-DWI的增加值监测III期非小细胞肺癌的治疗响应
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001 [O] . Kana Watanabe, Yukihiro Toi, Atsushi Nakamura, 2021

机译：尿嘧啶/ TEGAFUR和顺铂的随机期II试验与培养基和顺铂具有同时胸部放射治疗用于局部先进的不可切除阶段III非鳞状非小细胞肺癌：NJLCG1001
7. C3-03: Randomized, phase III Study of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (TRT) for unresectable stage III non-small-cell lung cancer (NSCLC): WJTOG0105 [O] . Yoshida Kimihide, Uejima Hisao, Satouchi Miyako, 2007

机译：C3-03：丝裂霉素/长春地辛/顺铂（MVP）与每周依立替康/卡铂（IC）或每周紫杉醇/卡铂（PC）联合胸腔放疗（TRT）进行不可切除的III期非小细胞III期随机研究肺癌（NSCLC）：WJTOG0105

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesin and cisplatin in unresectable stage III non small-cell lung cancer

著录项

引文网络

相似文献

相关主题

期刊订阅